Physician profile
Lon S Smith
NPI 1649204090
$8,837.34
in general payments reported to CMS, 2019-2025
34 companies · $1,059 in 2025
The $1,059 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,909 · 2020: $162 · 2021: $53.44 · 2022: $139 · 2023: $120 · 2024: $395 · 2025: $1,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,557 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,556.99 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $6,900.54 | 2019-2025 | Polivy, Lunsumio, Columvi |
| Daiichi Sankyo INC. | $343.93 | 2020-2025 | Enhertu, Injectafer, Datroway |
| Astrazeneca Pharmaceuticals LP | $314.05 | 2023-2025 | Enhertu, Lynparza |
| Novartis Pharmaceuticals Corporation | $177.36 | 2020-2025 | |
| Gilead Sciences, INC. | $102.01 | 2024-2025 | Trodelvy |
| Lilly USA, LLC | $101.23 | 2025 | Jaypirca, Verzenio |
| Celgene Corporation | $80.80 | 2025 | Opdualag, Reblozyl |
| Bayer Healthcare Pharmaceuticals INC. | $69.91 | 2019-2024 | |
| Foundation Medicine, INC. | $61.20 | 2020 | |
| Pfizer INC. | $58.52 | 2025 | |
| Janssen Biotech, INC. | $47.54 | 2025 | Tecvayli, Darzalex |
| Tersera Therapeutics LLC | $43.45 | 2025 | Zoladex |
| Astellas Pharma US INC | $41.13 | 2025 | Vyloy, Xtandi |
| E.R. Squibb & Sons, L.L.C. | $38.59 | 2020-2022 | |
| Abbvie INC. | $34.73 | 2019-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $34.68 | 2021-2025 | Monjuvi |
| Dendreon Pharmaceuticals LLC | $32.10 | 2025 | Provenge |
| Merck Sharp & Dohme LLC | $31.47 | 2025 | Welireg, Keytruda, Reblozyl |
| Medtronic USA, INC. | $28.24 | 2019 | |
| Amgen INC. | $25.07 | 2023 | Xgeva, Nplate |
| Alexion Pharmaceuticals, INC. | $24.89 | 2022 | |
| Cti Biopharma Corp. | $24.22 | 2022 | |
| Aveo Pharmaceuticals, INC. | $23.37 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.25 | 2022 | |
| Eisai INC. | $21.13 | 2020 | |
| Genzyme Corporation | $20.99 | 2025 | |
| Puma Biotechnology, INC. | $19.63 | 2021 | |
| Amneal Pharmaceuticals LLC | $19.24 | 2024 | Neulasta, Avastin, Neupogen |
| Progenics Pharmaceuticals, INC. | $18.46 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Genmab U.S., INC. | $15.82 | 2024 | Epkinly |
| Blueprint Medicines Corporation | $15.07 | 2025 | Ayvakit |
| Tempus Ai, INC | $14.70 | 2024 | |
| Mirati Therapeutics, INC. | $14.00 | 2023 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lon Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.